Global GLP-1 Receptor Agonist Anti-obesity Drug Market Growth 2026-2032
The global GLP-1 Receptor Agonist Anti-obesity Drug market size is predicted to grow from US$ 24215 million in 2025 to US$ 72176 million in 2032; it is expected to grow at a CAGR of 19.4% from 2026 to 2032.
GLP-1 receptor agonist anti-obesity drugs are prescription medicines that mimic or enhance glucagon-like peptide-1 activity to delay gastric emptying, increase satiety, reduce appetite and improve glucose metabolism, supporting long-term weight management in people with obesity or overweight with related risk factors. The category includes injectable products, oral formulations and long-acting modified dosage forms, with key evaluation metrics including weight-loss efficacy, durability, gastrointestinal tolerability, cardiometabolic benefit, dosing convenience and access. In 2025, global GLP-1 Receptor Agonist Anti-obesity Drugs production reached approximately 312 million unit.The average gross profit margin of this product is 80%.
The GLP-1 anti-obesity drug market is expanding rapidly amid rising obesity prevalence, stronger clinical evidence and higher patient willingness to pay. Originator companies are driving growth through capacity expansion, label expansion and improved dosing formats, while healthcare providers increasingly integrate pharmacological weight management into chronic disease care.
Competition is moving beyond weight-loss magnitude to durability, cardiovascular benefit, muscle-mass preservation, post-discontinuation rebound and affordability. Pen injectors remain the dominant format, while oral GLP-1 and longer-acting formulations may improve acceptance. However, manufacturing scale-up, cold chain requirements, supply shortages and pricing pressure remain major constraints.
Market growth is influenced by payer policy, reimbursement coverage, generic entry, online prescription compliance and drug safety monitoring. Future competition will center on differentiated clinical evidence, global capacity, supply-chain resilience and integrated chronic disease management services.
LP Information, Inc. (LPI) ' newest research report, the ?GLP-1 Receptor Agonist Anti-obesity Drug Industry Forecast? looks at past sales and reviews total world GLP-1 Receptor Agonist Anti-obesity Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected GLP-1 Receptor Agonist Anti-obesity Drug sales for 2026 through 2032. With GLP-1 Receptor Agonist Anti-obesity Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Receptor Agonist Anti-obesity Drug industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 Receptor Agonist Anti-obesity Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Receptor Agonist Anti-obesity Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global GLP-1 Receptor Agonist Anti-obesity Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Receptor Agonist Anti-obesity Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Receptor Agonist Anti-obesity Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Receptor Agonist Anti-obesity Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global GLP-1 Receptor Agonist Anti-obesity Drug market?
What factors are driving GLP-1 Receptor Agonist Anti-obesity Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GLP-1 Receptor Agonist Anti-obesity Drug market opportunities vary by end market size?
How does GLP-1 Receptor Agonist Anti-obesity Drug break out by Type, by Application?
GLP-1 receptor agonist anti-obesity drugs are prescription medicines that mimic or enhance glucagon-like peptide-1 activity to delay gastric emptying, increase satiety, reduce appetite and improve glucose metabolism, supporting long-term weight management in people with obesity or overweight with related risk factors. The category includes injectable products, oral formulations and long-acting modified dosage forms, with key evaluation metrics including weight-loss efficacy, durability, gastrointestinal tolerability, cardiometabolic benefit, dosing convenience and access. In 2025, global GLP-1 Receptor Agonist Anti-obesity Drugs production reached approximately 312 million unit.The average gross profit margin of this product is 80%.
The GLP-1 anti-obesity drug market is expanding rapidly amid rising obesity prevalence, stronger clinical evidence and higher patient willingness to pay. Originator companies are driving growth through capacity expansion, label expansion and improved dosing formats, while healthcare providers increasingly integrate pharmacological weight management into chronic disease care.
Competition is moving beyond weight-loss magnitude to durability, cardiovascular benefit, muscle-mass preservation, post-discontinuation rebound and affordability. Pen injectors remain the dominant format, while oral GLP-1 and longer-acting formulations may improve acceptance. However, manufacturing scale-up, cold chain requirements, supply shortages and pricing pressure remain major constraints.
Market growth is influenced by payer policy, reimbursement coverage, generic entry, online prescription compliance and drug safety monitoring. Future competition will center on differentiated clinical evidence, global capacity, supply-chain resilience and integrated chronic disease management services.
LP Information, Inc. (LPI) ' newest research report, the ?GLP-1 Receptor Agonist Anti-obesity Drug Industry Forecast? looks at past sales and reviews total world GLP-1 Receptor Agonist Anti-obesity Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected GLP-1 Receptor Agonist Anti-obesity Drug sales for 2026 through 2032. With GLP-1 Receptor Agonist Anti-obesity Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Receptor Agonist Anti-obesity Drug industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 Receptor Agonist Anti-obesity Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Receptor Agonist Anti-obesity Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global GLP-1 Receptor Agonist Anti-obesity Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Receptor Agonist Anti-obesity Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Receptor Agonist Anti-obesity Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Receptor Agonist Anti-obesity Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Semaglutide
- Liraglutide
- Oral GLP-1 Agonist
- Long-acting GLP-1 Agonist
- Generic Or Biosimilar GLP-1
- Next-generation GLP-1
- Other
- Injectable
- Oral Tablet
- Pen Injector
- Vial Or Cartridge
- Implantable Or Depot
- Other
- Prescription Obesity Treatment
- Diabetes With Weight Management
- Cardiometabolic Risk Reduction
- Adolescent Obesity
- Other
- Hospital Pharmacies
- Retail Pharmacies
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novo Nordisk
- Eli Lilly
- Huadong Medicine
- Renhui Bio
What is the 10-year outlook for the global GLP-1 Receptor Agonist Anti-obesity Drug market?
What factors are driving GLP-1 Receptor Agonist Anti-obesity Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GLP-1 Receptor Agonist Anti-obesity Drug market opportunities vary by end market size?
How does GLP-1 Receptor Agonist Anti-obesity Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for GLP-1 Receptor Agonist Anti-obesity Drug by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for GLP-1 Receptor Agonist Anti-obesity Drug by Country/Region, 2021, 2025 & 2032
2.2 GLP-1 Receptor Agonist Anti-obesity Drug Segment by Type
2.2.1 Semaglutide
2.2.2 Liraglutide
2.2.3 Oral GLP-1 Agonist
2.2.4 Long-acting GLP-1 Agonist
2.2.5 Generic Or Biosimilar GLP-1
2.2.6 Next-generation GLP-1
2.2.7 Other
2.2.8 GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type
2.2.8.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
2.2.8.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue and Market Share by Type (2021-2026)
2.2.8.3 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Type (2021-2026)
2.3 GLP-1 Receptor Agonist Anti-obesity Drug Segment by Dosage Form
2.3.1 Injectable
2.3.2 Oral Tablet
2.3.3 Pen Injector
2.3.4 Vial Or Cartridge
2.3.5 Implantable Or Depot
2.3.6 Other
2.3.7 GLP-1 Receptor Agonist Anti-obesity Drug Sales by Dosage Form
2.3.7.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Dosage Form (2021-2026)
2.3.7.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue and Market Share by Dosage Form (2021-2026)
2.3.7.3 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Dosage Form (2021-2026)
2.4 GLP-1 Receptor Agonist Anti-obesity Drug Segment by Indication
2.4.1 Prescription Obesity Treatment
2.4.2 Diabetes With Weight Management
2.4.3 Cardiometabolic Risk Reduction
2.4.4 Adolescent Obesity
2.4.5 Other
2.4.6 GLP-1 Receptor Agonist Anti-obesity Drug Sales by Indication
2.4.6.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Indication (2021-2026)
2.4.6.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue and Market Share by Indication (2021-2026)
2.4.6.3 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Indication (2021-2026)
2.5 GLP-1 Receptor Agonist Anti-obesity Drug Segment by Application
2.5.1 Hospital Pharmacies
2.5.2 Retail Pharmacies
2.5.3 Other
2.5.4 GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application
2.5.4.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Market Share by Application (2021-2026)
2.5.4.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Breakdown Data by Company
3.1.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales by Company (2021-2026)
3.1.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Company (2021-2026)
3.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue by Company (2021-2026)
3.2.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Company (2021-2026)
3.2.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Company (2021-2026)
3.3 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Company
3.4 Key Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Product Location Distribution
3.4.2 Players GLP-1 Receptor Agonist Anti-obesity Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GLP-1 RECEPTOR AGONIST ANTI-OBESITY DRUG BY GEOGRAPHIC REGION
4.1 World Historic GLP-1 Receptor Agonist Anti-obesity Drug Market Size by Geographic Region (2021-2026)
4.1.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales by Geographic Region (2021-2026)
4.1.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic GLP-1 Receptor Agonist Anti-obesity Drug Market Size by Country/Region (2021-2026)
4.2.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales by Country/Region (2021-2026)
4.2.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Growth
4.4 APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Growth
4.5 Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales Growth
4.6 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales Growth
5 AMERICAS
5.1 Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country
5.1.1 Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026)
5.1.2 Americas GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country (2021-2026)
5.2 Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026)
5.3 Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Region
6.1.1 APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Region (2021-2026)
6.1.2 APAC GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Region (2021-2026)
6.2 APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026)
6.3 APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe GLP-1 Receptor Agonist Anti-obesity Drug by Country
7.1.1 Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026)
7.1.2 Europe GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country (2021-2026)
7.2 Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026)
7.3 Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug by Country
8.1.1 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026)
8.1.2 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country (2021-2026)
8.2 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026)
8.3 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of GLP-1 Receptor Agonist Anti-obesity Drug
10.3 Manufacturing Process Analysis of GLP-1 Receptor Agonist Anti-obesity Drug
10.4 Industry Chain Structure of GLP-1 Receptor Agonist Anti-obesity Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 GLP-1 Receptor Agonist Anti-obesity Drug Distributors
11.3 GLP-1 Receptor Agonist Anti-obesity Drug Customer
12 WORLD FORECAST REVIEW FOR GLP-1 RECEPTOR AGONIST ANTI-OBESITY DRUG BY GEOGRAPHIC REGION
12.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Market Size Forecast by Region
12.1.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Forecast by Region (2027-2032)
12.1.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global GLP-1 Receptor Agonist Anti-obesity Drug Forecast by Type (2027-2032)
12.7 Global GLP-1 Receptor Agonist Anti-obesity Drug Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
13.1.3 Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
13.2.3 Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 Huadong Medicine
13.3.1 Huadong Medicine Company Information
13.3.2 Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
13.3.3 Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Huadong Medicine Main Business Overview
13.3.5 Huadong Medicine Latest Developments
13.4 Renhui Bio
13.4.1 Renhui Bio Company Information
13.4.2 Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
13.4.3 Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Renhui Bio Main Business Overview
13.4.5 Renhui Bio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for GLP-1 Receptor Agonist Anti-obesity Drug by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for GLP-1 Receptor Agonist Anti-obesity Drug by Country/Region, 2021, 2025 & 2032
2.2 GLP-1 Receptor Agonist Anti-obesity Drug Segment by Type
2.2.1 Semaglutide
2.2.2 Liraglutide
2.2.3 Oral GLP-1 Agonist
2.2.4 Long-acting GLP-1 Agonist
2.2.5 Generic Or Biosimilar GLP-1
2.2.6 Next-generation GLP-1
2.2.7 Other
2.2.8 GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type
2.2.8.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
2.2.8.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue and Market Share by Type (2021-2026)
2.2.8.3 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Type (2021-2026)
2.3 GLP-1 Receptor Agonist Anti-obesity Drug Segment by Dosage Form
2.3.1 Injectable
2.3.2 Oral Tablet
2.3.3 Pen Injector
2.3.4 Vial Or Cartridge
2.3.5 Implantable Or Depot
2.3.6 Other
2.3.7 GLP-1 Receptor Agonist Anti-obesity Drug Sales by Dosage Form
2.3.7.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Dosage Form (2021-2026)
2.3.7.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue and Market Share by Dosage Form (2021-2026)
2.3.7.3 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Dosage Form (2021-2026)
2.4 GLP-1 Receptor Agonist Anti-obesity Drug Segment by Indication
2.4.1 Prescription Obesity Treatment
2.4.2 Diabetes With Weight Management
2.4.3 Cardiometabolic Risk Reduction
2.4.4 Adolescent Obesity
2.4.5 Other
2.4.6 GLP-1 Receptor Agonist Anti-obesity Drug Sales by Indication
2.4.6.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Indication (2021-2026)
2.4.6.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue and Market Share by Indication (2021-2026)
2.4.6.3 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Indication (2021-2026)
2.5 GLP-1 Receptor Agonist Anti-obesity Drug Segment by Application
2.5.1 Hospital Pharmacies
2.5.2 Retail Pharmacies
2.5.3 Other
2.5.4 GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application
2.5.4.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Market Share by Application (2021-2026)
2.5.4.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Breakdown Data by Company
3.1.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales by Company (2021-2026)
3.1.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Company (2021-2026)
3.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue by Company (2021-2026)
3.2.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Company (2021-2026)
3.2.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Company (2021-2026)
3.3 Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Company
3.4 Key Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Product Location Distribution
3.4.2 Players GLP-1 Receptor Agonist Anti-obesity Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GLP-1 RECEPTOR AGONIST ANTI-OBESITY DRUG BY GEOGRAPHIC REGION
4.1 World Historic GLP-1 Receptor Agonist Anti-obesity Drug Market Size by Geographic Region (2021-2026)
4.1.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales by Geographic Region (2021-2026)
4.1.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic GLP-1 Receptor Agonist Anti-obesity Drug Market Size by Country/Region (2021-2026)
4.2.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales by Country/Region (2021-2026)
4.2.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Growth
4.4 APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Growth
4.5 Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales Growth
4.6 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales Growth
5 AMERICAS
5.1 Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country
5.1.1 Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026)
5.1.2 Americas GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country (2021-2026)
5.2 Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026)
5.3 Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Region
6.1.1 APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Region (2021-2026)
6.1.2 APAC GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Region (2021-2026)
6.2 APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026)
6.3 APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe GLP-1 Receptor Agonist Anti-obesity Drug by Country
7.1.1 Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026)
7.1.2 Europe GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country (2021-2026)
7.2 Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026)
7.3 Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug by Country
8.1.1 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026)
8.1.2 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country (2021-2026)
8.2 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026)
8.3 Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of GLP-1 Receptor Agonist Anti-obesity Drug
10.3 Manufacturing Process Analysis of GLP-1 Receptor Agonist Anti-obesity Drug
10.4 Industry Chain Structure of GLP-1 Receptor Agonist Anti-obesity Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 GLP-1 Receptor Agonist Anti-obesity Drug Distributors
11.3 GLP-1 Receptor Agonist Anti-obesity Drug Customer
12 WORLD FORECAST REVIEW FOR GLP-1 RECEPTOR AGONIST ANTI-OBESITY DRUG BY GEOGRAPHIC REGION
12.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Market Size Forecast by Region
12.1.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Forecast by Region (2027-2032)
12.1.2 Global GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global GLP-1 Receptor Agonist Anti-obesity Drug Forecast by Type (2027-2032)
12.7 Global GLP-1 Receptor Agonist Anti-obesity Drug Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
13.1.3 Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
13.2.3 Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 Huadong Medicine
13.3.1 Huadong Medicine Company Information
13.3.2 Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
13.3.3 Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Huadong Medicine Main Business Overview
13.3.5 Huadong Medicine Latest Developments
13.4 Renhui Bio
13.4.1 Renhui Bio Company Information
13.4.2 Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
13.4.3 Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Renhui Bio Main Business Overview
13.4.5 Renhui Bio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Semaglutide
Table 4. Major Players of Liraglutide
Table 5. Major Players of Oral GLP-1 Agonist
Table 6. Major Players of Long-acting GLP-1 Agonist
Table 7. Major Players of Generic Or Biosimilar GLP-1
Table 8. Major Players of Next-generation GLP-1
Table 9. Major Players of Other
Table 10. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026) & (K Units)
Table 11. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
Table 12. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Type (2021-2026) & ($ million)
Table 13. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Type (2021-2026)
Table 14. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Type (2021-2026) & (US$/Unit)
Table 15. Major Players of Injectable
Table 16. Major Players of OralTablet
Table 17. Major Players of Pen Injector
Table 18. Major Players of Vial Or Cartridge
Table 19. Major Players of Implantable Or Depot
Table 20. Major Players of Other
Table 21. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Dosage Form (2021-2026) & (K Units)
Table 22. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Dosage Form (2021-2026)
Table 23. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Dosage Form (2021-2026) & ($ million)
Table 24. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Dosage Form (2021-2026)
Table 25. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Dosage Form (2021-2026) & (US$/Unit)
Table 26. Major Players of Prescription Obesity Treatment
Table 27. Major Players of Diabetes With Weight Management
Table 28. Major Players of Cardiometabolic Risk Reduction
Table 29. Major Players of Adolescent Obesity
Table 30. Major Players of Other
Table 31. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Indication (2021-2026) & (K Units)
Table 32. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Indication (2021-2026)
Table 33. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Indication (2021-2026) & ($ million)
Table 34. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Indication (2021-2026)
Table 35. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Indication (2021-2026) & (US$/Unit)
Table 36. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale by Application (2021-2026) & (K Units)
Table 37. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Market Share by Application (2021-2026)
Table 38. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Application (2021-2026) & ($ million)
Table 39. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Application (2021-2026)
Table 40. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Application (2021-2026) & (US$/Unit)
Table 41. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Company (2021-2026) & (K Units)
Table 42. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Company (2021-2026)
Table 43. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Company (2021-2026) & ($ millions)
Table 44. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Company (2021-2026)
Table 45. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Company (2021-2026) & (US$/Unit)
Table 46. Key Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Producing Area Distribution and Sales Area
Table 47. Players GLP-1 Receptor Agonist Anti-obesity Drug Products Offered
Table 48. GLP-1 Receptor Agonist Anti-obesity Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 49. New Products and Potential Entrants
Table 50. Market M&A Activity & Strategy
Table 51. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Geographic Region (2021-2026) & (K Units)
Table 52. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share Geographic Region (2021-2026)
Table 53. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Geographic Region (2021-2026) & ($ millions)
Table 54. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Geographic Region (2021-2026)
Table 55. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country/Region (2021-2026) & (K Units)
Table 56. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country/Region (2021-2026)
Table 57. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 58. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Country/Region (2021-2026)
Table 59. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026) & (K Units)
Table 60. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country (2021-2026)
Table 61. Americas GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country (2021-2026) & ($ millions)
Table 62. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026) & (K Units)
Table 63. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026) & (K Units)
Table 64. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Region (2021-2026) & (K Units)
Table 65. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Region (2021-2026)
Table 66. APAC GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Region (2021-2026) & ($ millions)
Table 67. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026) & (K Units)
Table 68. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026) & (K Units)
Table 69. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026) & (K Units)
Table 70. Europe GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country (2021-2026) & ($ millions)
Table 71. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026) & (K Units)
Table 72. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026) & (K Units)
Table 73. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026) & (K Units)
Table 74. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Country (2021-2026)
Table 75. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026) & (K Units)
Table 76. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026) & (K Units)
Table 77. Key Market Drivers & Growth Opportunities of GLP-1 Receptor Agonist Anti-obesity Drug
Table 78. Key Market Challenges & Risks of GLP-1 Receptor Agonist Anti-obesity Drug
Table 79. Key Industry Trends of GLP-1 Receptor Agonist Anti-obesity Drug
Table 80. GLP-1 Receptor Agonist Anti-obesity Drug Raw Material
Table 81. Key Suppliers of Raw Materials
Table 82. GLP-1 Receptor Agonist Anti-obesity Drug Distributors List
Table 83. GLP-1 Receptor Agonist Anti-obesity Drug Customer List
Table 84. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 85. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Forecast by Region (2027-2032) & ($ millions)
Table 86. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 87. Americas GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 88. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 89. APAC GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 90. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 91. Europe GLP-1 Receptor Agonist Anti-obesity Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 92. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 93. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 94. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Type (2027-2032) & (K Units)
Table 95. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Forecast by Type (2027-2032) & ($ millions)
Table 96. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Application (2027-2032) & (K Units)
Table 97. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Forecast by Application (2027-2032) & ($ millions)
Table 98. Novo Nordisk Basic Information, GLP-1 Receptor Agonist Anti-obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
Table 100. Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Novo Nordisk Main Business
Table 102. Novo Nordisk Latest Developments
Table 103. Eli Lilly Basic Information, GLP-1 Receptor Agonist Anti-obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
Table 105. Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Eli Lilly Main Business
Table 107. Eli Lilly Latest Developments
Table 108. Huadong Medicine Basic Information, GLP-1 Receptor Agonist Anti-obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
Table 110. Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Huadong Medicine Main Business
Table 112. Huadong Medicine Latest Developments
Table 113. Renhui Bio Basic Information, GLP-1 Receptor Agonist Anti-obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
Table 115. Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Renhui Bio Main Business
Table 117. Renhui Bio Latest Developments
Table 1. GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. GLP-1 Receptor Agonist Anti-obesity Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Semaglutide
Table 4. Major Players of Liraglutide
Table 5. Major Players of Oral GLP-1 Agonist
Table 6. Major Players of Long-acting GLP-1 Agonist
Table 7. Major Players of Generic Or Biosimilar GLP-1
Table 8. Major Players of Next-generation GLP-1
Table 9. Major Players of Other
Table 10. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026) & (K Units)
Table 11. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
Table 12. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Type (2021-2026) & ($ million)
Table 13. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Type (2021-2026)
Table 14. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Type (2021-2026) & (US$/Unit)
Table 15. Major Players of Injectable
Table 16. Major Players of OralTablet
Table 17. Major Players of Pen Injector
Table 18. Major Players of Vial Or Cartridge
Table 19. Major Players of Implantable Or Depot
Table 20. Major Players of Other
Table 21. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Dosage Form (2021-2026) & (K Units)
Table 22. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Dosage Form (2021-2026)
Table 23. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Dosage Form (2021-2026) & ($ million)
Table 24. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Dosage Form (2021-2026)
Table 25. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Dosage Form (2021-2026) & (US$/Unit)
Table 26. Major Players of Prescription Obesity Treatment
Table 27. Major Players of Diabetes With Weight Management
Table 28. Major Players of Cardiometabolic Risk Reduction
Table 29. Major Players of Adolescent Obesity
Table 30. Major Players of Other
Table 31. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Indication (2021-2026) & (K Units)
Table 32. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Indication (2021-2026)
Table 33. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Indication (2021-2026) & ($ million)
Table 34. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Indication (2021-2026)
Table 35. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Indication (2021-2026) & (US$/Unit)
Table 36. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale by Application (2021-2026) & (K Units)
Table 37. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Market Share by Application (2021-2026)
Table 38. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Application (2021-2026) & ($ million)
Table 39. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Application (2021-2026)
Table 40. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Application (2021-2026) & (US$/Unit)
Table 41. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Company (2021-2026) & (K Units)
Table 42. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Company (2021-2026)
Table 43. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Company (2021-2026) & ($ millions)
Table 44. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Company (2021-2026)
Table 45. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Price by Company (2021-2026) & (US$/Unit)
Table 46. Key Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Producing Area Distribution and Sales Area
Table 47. Players GLP-1 Receptor Agonist Anti-obesity Drug Products Offered
Table 48. GLP-1 Receptor Agonist Anti-obesity Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 49. New Products and Potential Entrants
Table 50. Market M&A Activity & Strategy
Table 51. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Geographic Region (2021-2026) & (K Units)
Table 52. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share Geographic Region (2021-2026)
Table 53. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Geographic Region (2021-2026) & ($ millions)
Table 54. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Geographic Region (2021-2026)
Table 55. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country/Region (2021-2026) & (K Units)
Table 56. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country/Region (2021-2026)
Table 57. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 58. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Country/Region (2021-2026)
Table 59. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026) & (K Units)
Table 60. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country (2021-2026)
Table 61. Americas GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country (2021-2026) & ($ millions)
Table 62. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026) & (K Units)
Table 63. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026) & (K Units)
Table 64. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Region (2021-2026) & (K Units)
Table 65. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Region (2021-2026)
Table 66. APAC GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Region (2021-2026) & ($ millions)
Table 67. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026) & (K Units)
Table 68. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026) & (K Units)
Table 69. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026) & (K Units)
Table 70. Europe GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Country (2021-2026) & ($ millions)
Table 71. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026) & (K Units)
Table 72. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026) & (K Units)
Table 73. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Country (2021-2026) & (K Units)
Table 74. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Country (2021-2026)
Table 75. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Type (2021-2026) & (K Units)
Table 76. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales by Application (2021-2026) & (K Units)
Table 77. Key Market Drivers & Growth Opportunities of GLP-1 Receptor Agonist Anti-obesity Drug
Table 78. Key Market Challenges & Risks of GLP-1 Receptor Agonist Anti-obesity Drug
Table 79. Key Industry Trends of GLP-1 Receptor Agonist Anti-obesity Drug
Table 80. GLP-1 Receptor Agonist Anti-obesity Drug Raw Material
Table 81. Key Suppliers of Raw Materials
Table 82. GLP-1 Receptor Agonist Anti-obesity Drug Distributors List
Table 83. GLP-1 Receptor Agonist Anti-obesity Drug Customer List
Table 84. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 85. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Forecast by Region (2027-2032) & ($ millions)
Table 86. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 87. Americas GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 88. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 89. APAC GLP-1 Receptor Agonist Anti-obesity Drug Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 90. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 91. Europe GLP-1 Receptor Agonist Anti-obesity Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 92. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 93. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 94. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Type (2027-2032) & (K Units)
Table 95. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Forecast by Type (2027-2032) & ($ millions)
Table 96. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Forecast by Application (2027-2032) & (K Units)
Table 97. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Forecast by Application (2027-2032) & ($ millions)
Table 98. Novo Nordisk Basic Information, GLP-1 Receptor Agonist Anti-obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
Table 100. Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Novo Nordisk Main Business
Table 102. Novo Nordisk Latest Developments
Table 103. Eli Lilly Basic Information, GLP-1 Receptor Agonist Anti-obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
Table 105. Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Eli Lilly Main Business
Table 107. Eli Lilly Latest Developments
Table 108. Huadong Medicine Basic Information, GLP-1 Receptor Agonist Anti-obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
Table 110. Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Huadong Medicine Main Business
Table 112. Huadong Medicine Latest Developments
Table 113. Renhui Bio Basic Information, GLP-1 Receptor Agonist Anti-obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Product Portfolios and Specifications
Table 115. Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Renhui Bio Main Business
Table 117. Renhui Bio Latest Developments
LIST OF FIGURES
Figure 1. Picture of GLP-1 Receptor Agonist Anti-obesity Drug
Figure 2. GLP-1 Receptor Agonist Anti-obesity Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. GLP-1 Receptor Agonist Anti-obesity Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country/Region (2025)
Figure 10. GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Semaglutide
Figure 12. Product Picture of Liraglutide
Figure 13. Product Picture of Oral GLP-1 Agonist
Figure 14. Product Picture of Long-acting GLP-1 Agonist
Figure 15. Product Picture of Generic Or Biosimilar GLP-1
Figure 16. Product Picture of Next-generation GLP-1
Figure 17. Product Picture of Other
Figure 18. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type in 2026
Figure 19. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Type (2021-2026)
Figure 20. Product Picture of Injectable
Figure 21. Product Picture of OralTablet
Figure 22. Product Picture of Pen Injector
Figure 23. Product Picture of Vial Or Cartridge
Figure 24. Product Picture of Implantable Or Depot
Figure 25. Product Picture of Other
Figure 26. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Dosage Form in 2026
Figure 27. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Dosage Form (2021-2026)
Figure 28. Product Picture of Prescription Obesity Treatment
Figure 29. Product Picture of Diabetes With Weight Management
Figure 30. Product Picture of Cardiometabolic Risk Reduction
Figure 31. Product Picture of Adolescent Obesity
Figure 32. Product Picture of Other
Figure 33. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Indication in 2026
Figure 34. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Indication (2021-2026)
Figure 35. GLP-1 Receptor Agonist Anti-obesity Drug Consumed in Hospital Pharmacies
Figure 36. Global GLP-1 Receptor Agonist Anti-obesity Drug Market: Hospital Pharmacies (2021-2026) & (K Units)
Figure 37. GLP-1 Receptor Agonist Anti-obesity Drug Consumed in Retail Pharmacies
Figure 38. Global GLP-1 Receptor Agonist Anti-obesity Drug Market: Retail Pharmacies (2021-2026) & (K Units)
Figure 39. GLP-1 Receptor Agonist Anti-obesity Drug Consumed in Other
Figure 40. Global GLP-1 Receptor Agonist Anti-obesity Drug Market: Other (2021-2026) & (K Units)
Figure 41. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Market Share by Application (2025)
Figure 42. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Application in 2025
Figure 43. GLP-1 Receptor Agonist Anti-obesity Drug Sales by Company in 2025 (K Units)
Figure 44. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Company in 2025
Figure 45. GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Company in 2025 ($ millions)
Figure 46. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Company in 2025
Figure 47. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Geographic Region (2021-2026)
Figure 48. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Geographic Region in 2025
Figure 49. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales 2021-2026 (K Units)
Figure 50. Americas GLP-1 Receptor Agonist Anti-obesity Drug Revenue 2021-2026 ($ millions)
Figure 51. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales 2021-2026 (K Units)
Figure 52. APAC GLP-1 Receptor Agonist Anti-obesity Drug Revenue 2021-2026 ($ millions)
Figure 53. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales 2021-2026 (K Units)
Figure 54. Europe GLP-1 Receptor Agonist Anti-obesity Drug Revenue 2021-2026 ($ millions)
Figure 55. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales 2021-2026 (K Units)
Figure 56. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Revenue 2021-2026 ($ millions)
Figure 57. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country in 2025
Figure 58. Americas GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Country (2021-2026)
Figure 59. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
Figure 60. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Application (2021-2026)
Figure 61. United States GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 62. Canada GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 63. Mexico GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 64. Brazil GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 65. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Region in 2025
Figure 66. APAC GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Region (2021-2026)
Figure 67. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
Figure 68. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Application (2021-2026)
Figure 69. China GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 70. Japan GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 71. South Korea GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 72. Southeast Asia GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 73. India GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 74. Australia GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 75. China Taiwan GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 76. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country in 2025
Figure 77. Europe GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Country (2021-2026)
Figure 78. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
Figure 79. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Application (2021-2026)
Figure 80. Germany GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 81. France GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 82. UK GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 83. Italy GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 84. Russia GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 85. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country (2021-2026)
Figure 86. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
Figure 87. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Application (2021-2026)
Figure 88. Egypt GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 89. South Africa GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 90. Israel GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 91. Turkey GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 92. GCC Countries GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 93. Manufacturing Cost Structure Analysis of GLP-1 Receptor Agonist Anti-obesity Drug in 2026
Figure 94. Manufacturing Process Analysis of GLP-1 Receptor Agonist Anti-obesity Drug
Figure 95. Industry Chain Structure of GLP-1 Receptor Agonist Anti-obesity Drug
Figure 96. Channels of Distribution
Figure 97. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Forecast by Region (2027-2032)
Figure 98. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share Forecast by Region (2027-2032)
Figure 99. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share Forecast by Type (2027-2032)
Figure 100. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share Forecast by Type (2027-2032)
Figure 101. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share Forecast by Application (2027-2032)
Figure 102. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of GLP-1 Receptor Agonist Anti-obesity Drug
Figure 2. GLP-1 Receptor Agonist Anti-obesity Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. GLP-1 Receptor Agonist Anti-obesity Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country/Region (2025)
Figure 10. GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Semaglutide
Figure 12. Product Picture of Liraglutide
Figure 13. Product Picture of Oral GLP-1 Agonist
Figure 14. Product Picture of Long-acting GLP-1 Agonist
Figure 15. Product Picture of Generic Or Biosimilar GLP-1
Figure 16. Product Picture of Next-generation GLP-1
Figure 17. Product Picture of Other
Figure 18. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type in 2026
Figure 19. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Type (2021-2026)
Figure 20. Product Picture of Injectable
Figure 21. Product Picture of OralTablet
Figure 22. Product Picture of Pen Injector
Figure 23. Product Picture of Vial Or Cartridge
Figure 24. Product Picture of Implantable Or Depot
Figure 25. Product Picture of Other
Figure 26. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Dosage Form in 2026
Figure 27. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Dosage Form (2021-2026)
Figure 28. Product Picture of Prescription Obesity Treatment
Figure 29. Product Picture of Diabetes With Weight Management
Figure 30. Product Picture of Cardiometabolic Risk Reduction
Figure 31. Product Picture of Adolescent Obesity
Figure 32. Product Picture of Other
Figure 33. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Indication in 2026
Figure 34. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Indication (2021-2026)
Figure 35. GLP-1 Receptor Agonist Anti-obesity Drug Consumed in Hospital Pharmacies
Figure 36. Global GLP-1 Receptor Agonist Anti-obesity Drug Market: Hospital Pharmacies (2021-2026) & (K Units)
Figure 37. GLP-1 Receptor Agonist Anti-obesity Drug Consumed in Retail Pharmacies
Figure 38. Global GLP-1 Receptor Agonist Anti-obesity Drug Market: Retail Pharmacies (2021-2026) & (K Units)
Figure 39. GLP-1 Receptor Agonist Anti-obesity Drug Consumed in Other
Figure 40. Global GLP-1 Receptor Agonist Anti-obesity Drug Market: Other (2021-2026) & (K Units)
Figure 41. Global GLP-1 Receptor Agonist Anti-obesity Drug Sale Market Share by Application (2025)
Figure 42. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Application in 2025
Figure 43. GLP-1 Receptor Agonist Anti-obesity Drug Sales by Company in 2025 (K Units)
Figure 44. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Company in 2025
Figure 45. GLP-1 Receptor Agonist Anti-obesity Drug Revenue by Company in 2025 ($ millions)
Figure 46. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Company in 2025
Figure 47. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Geographic Region (2021-2026)
Figure 48. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Geographic Region in 2025
Figure 49. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales 2021-2026 (K Units)
Figure 50. Americas GLP-1 Receptor Agonist Anti-obesity Drug Revenue 2021-2026 ($ millions)
Figure 51. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales 2021-2026 (K Units)
Figure 52. APAC GLP-1 Receptor Agonist Anti-obesity Drug Revenue 2021-2026 ($ millions)
Figure 53. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales 2021-2026 (K Units)
Figure 54. Europe GLP-1 Receptor Agonist Anti-obesity Drug Revenue 2021-2026 ($ millions)
Figure 55. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales 2021-2026 (K Units)
Figure 56. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Revenue 2021-2026 ($ millions)
Figure 57. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country in 2025
Figure 58. Americas GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Country (2021-2026)
Figure 59. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
Figure 60. Americas GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Application (2021-2026)
Figure 61. United States GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 62. Canada GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 63. Mexico GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 64. Brazil GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 65. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Region in 2025
Figure 66. APAC GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Region (2021-2026)
Figure 67. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
Figure 68. APAC GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Application (2021-2026)
Figure 69. China GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 70. Japan GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 71. South Korea GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 72. Southeast Asia GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 73. India GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 74. Australia GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 75. China Taiwan GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 76. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country in 2025
Figure 77. Europe GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share by Country (2021-2026)
Figure 78. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
Figure 79. Europe GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Application (2021-2026)
Figure 80. Germany GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 81. France GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 82. UK GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 83. Italy GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 84. Russia GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 85. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Country (2021-2026)
Figure 86. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Type (2021-2026)
Figure 87. Middle East & Africa GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share by Application (2021-2026)
Figure 88. Egypt GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 89. South Africa GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 90. Israel GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 91. Turkey GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 92. GCC Countries GLP-1 Receptor Agonist Anti-obesity Drug Revenue Growth 2021-2026 ($ millions)
Figure 93. Manufacturing Cost Structure Analysis of GLP-1 Receptor Agonist Anti-obesity Drug in 2026
Figure 94. Manufacturing Process Analysis of GLP-1 Receptor Agonist Anti-obesity Drug
Figure 95. Industry Chain Structure of GLP-1 Receptor Agonist Anti-obesity Drug
Figure 96. Channels of Distribution
Figure 97. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Forecast by Region (2027-2032)
Figure 98. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share Forecast by Region (2027-2032)
Figure 99. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share Forecast by Type (2027-2032)
Figure 100. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share Forecast by Type (2027-2032)
Figure 101. Global GLP-1 Receptor Agonist Anti-obesity Drug Sales Market Share Forecast by Application (2027-2032)
Figure 102. Global GLP-1 Receptor Agonist Anti-obesity Drug Revenue Market Share Forecast by Application (2027-2032)
